- A global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines.
- The proprietary lipid nanoparticle delivery system (LUNAR®), as well as the proprietary Self-Transcribing and Replicating RNA technology (STARR™), with the potential to enable multiple nucleic acid medicines and provide longer-lasting RNA and sustained protein expression at lower dose levels.
- Pipeline includes COVID-19 and Influenza vaccines, ornithine transcarbamylase (OTC) deficiency and cystic fibrosis.
